Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12638825 | 0.93 | ADORA3 (0.44) | ADORA3ADORA2AADORA1KDM4EMAPT | |
| SCHEMBL12638821 | 0.90 | ADORA1 (0.49) | ADORA3ADORA2AADORA1KDM4EMAPT | |
| SCHEMBL12638829 | 0.83 | MAPT (0.43) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL12638818 | 0.81 | ADORA3 (0.46) | ADORA3ADORA2AADORA1KDM4EMAPT | |
| SCHEMBL12638839 | 0.76 | CHEK1 (0.47) | KDRCHEK1 | |
| SCHEMBL12638819 | 0.76 | KDR (0.40) | ADORA3ADORA2AADORA1KDM4EMAPT | |
| SCHEMBL12638816 | 0.74 | GSK3B (0.45) | ADORA3ADORA2AADORA1KDM4EMAPT | |
| SCHEMBL12638830 | 0.73 | PRMT5 (0.41) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL12639901 | 0.72 | KDM4E (0.42) | KDM4EMAPTRAB9AMEN1ALDH1A1 | |
| SCHEMBL12638840 | 0.71 | CHEK1 (0.46) | KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | ADORA3 54/4885ADORA2A 18/4885ADORA1 50/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | ADORA3 455/4885ADORA2A 125/4885ADORA1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.